Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The FOREMOST Study: Apremilast in PsA
Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
Watch video →
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read more →
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read more →
Effects of Apremilast on Cardiometabolic Effects in PsA
Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
An Interview with Kevin Winthrop: Three Questions About COVID 19
Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.
Watch video →
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Dr. John Cush RheumNow
2 years 1 month ago
#PMR with Cancer
Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation?
https://t.co/GsQ5FoDGPK https://t.co/ybHMmi72TG
Dr. John Cush RheumNow
2 years 1 month ago
Innovative, full-read, state-of-the-art article on IMAGING in INFLAMMATORY ARTHRITIS & its future role in precision medicine. "Imaging is poised to become an invaluable tool in precision medicine..". HR-pQCT, 3T or 7T MRI, FAPI PET–CT, CEUS, FOI, etc https://t.co/fGQVEOkea9 https://t.co/XyvtZj85Hk
Dr. John Cush RheumNow
2 years 1 month ago
Check out my other podcast - the Miracle Larry Podcast. Miracle Larry gave the keynote lecture at RNL2023. A podcast focused on his amazing story. Follow us @Miracle_LarryK. We’d appreciate the support!
https://t.co/6zi2D7hdGJ
Dr. John Cush RheumNow
2 years 1 month ago
What Goes Wrong with the Immune System in #PMR?
https://t.co/3DDFXBOfaL https://t.co/WNiWpokP4q
Dr. John Cush RheumNow
2 years 1 month ago
Using Methotrexate in #PMR
Where in other inflammatory rheumatic disorders, such as RA and PsA, early initiation of MTX is common practice, this is not the case in PMR. Treatment of PMR is still largely based on GC.
https://t.co/pQtmYvF2NS https://t.co/wJTpFPqmlw
Dr. John Cush RheumNow
2 years 1 month ago
#PMR and Palindromic Rheumatism Similarities
https://t.co/uJ4hJSA0hL https://t.co/rFINkKZh7l
Dr. John Cush RheumNow
2 years 1 month ago
Check out the latest therapeutic update for axSpA in this video series dedicated to creating a better understanding of treatment goals.https://t.co/VTQI0SzHpO https://t.co/H3yBcnUvwu
Dr. John Cush RheumNow
2 years 1 month ago
2023 EULAR Lupus Management Recommendations
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
https://t.co/Fzh8F33u3U https://t.co/2baAVsm8Bo
Dr. John Cush RheumNow
2 years 1 month ago
IL-2 receptor (sCD25) levels as a biomarker of RA-ILD? Study of 294 RA pts (56 w/ ILD) & 58 healthy controls (HCs) (ILD confirmed by HRCT). sCD25 sensitivity 51% & specificity 77%,; it elevated in RA-ILD subtypes (UIP, NSIP); but didnt correlate w/ HRCT https://t.co/1gJ635tu8a https://t.co/aYamfJwJi2
PMR might be one of the most rewarding diagnoses to make in real practice: the patient comes to you in severe debilitating pain, and you prescribe steroids, giving them their lives back! As much as this impressive response makes your intervention appear almost magical, there is the often-forgotten story about the implications of such a diagnosis and treatment on patients' daily lives.
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
Poster Hall